Form 4: Y-mAbs Therapeutics Executive Joris Wilms Reports Stock and Option Grants

SVP and Chief Operating Officer of Y-mAbs Therapeutics, Joris Wilms, reports the acquisition of restricted stock units and stock options.

Summary

• Joris Wilms, SVP and Chief Operating Officer of Y-mAbs Therapeutics, reported the acquisition of 21,500 restricted stock units (RSUs) and 42,900 stock options on January 17, 2025.
• The RSUs were granted under the company's 2018 Equity Incentive Plan and will vest in three equal installments on January 17, 2026, 2027, and 2028, contingent on continued service.
• The stock options, also granted under the 2018 plan, vest as to 25% on January 17, 2026, and then in equal monthly installments until fully vested, also contingent on continued service.
• Following these transactions, Wilms beneficially owns 52,100 shares of common stock and 42,900 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grants of RSUs and stock options align the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The vesting of the RSUs and stock options is contingent on continued service, which could be a risk if the executive leaves the company before full vesting.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector where long-term growth is a key focus.

Comparison to Industry Standards

• Equity grants are a common form of compensation for executives in the biotechnology industry.
• Companies like Amgen, Regeneron, and Gilead Sciences also use stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules described are typical for these types of grants, designed to retain talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with long-term company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, insider trading, executive compensation, form 4, Y-mAbs Therapeutics, Joris Wilms